{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:54:31Z","timestamp":1785128071853,"version":"3.55.0"},"reference-count":19,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2021,7,24]]},"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with multiple poor prognostic factors (PPFs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a post hoc analysis of the phase III, randomised, double-blind, active-controlled, FINCH 3 study (clinicaltrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02886728\">NCT02886728<\/jats:ext-link>). Patients received once-daily oral filgotinib 200 or 100\u2009mg plus once-weekly oral MTX \u226420\u2009mg (FIL200 + MTX\u2009and FIL100 + MTX), filgotinib 200\u2009mg monotherapy (FIL200), or oral MTX monotherapy (MTX-mono) for up to 52 weeks. PPFs investigated were seropositivity for rheumatoid factor or anticyclic citrullinated peptide antibodies, high-sensitivity C reactive protein (CRP) \u22654\u2009mg\/L, Disease Activity Score in 28 joints with CRP (DAS28(CRP)) &gt;5.1, and presence of erosions. Filgotinib efficacy and safety in patients with all four PPFs at baseline were explored versus MTX-mono within this subgroup and compared informally with the overall population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 1249 patients in FINCH 3, 510 (40.8%) had all PPFs. Efficacy of FIL200 + MTX among these patients was comparable to the overall population, with higher rates of 20%\/50%\/70% improvement from baseline by American College of Rheumatology criteria, DAS28(CRP) &lt;2.6, and remission; greater improvement in physical function and pain; and better inhibition of structural damage relative to MTX-mono. FIL100 + MTX\u2009and FIL200 were not consistently more efficacious versus MTX-mono. Safety of filgotinib in patients with PPFs was comparable to the overall population; no new safety signals were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>FIL200 + MTX efficacy and safety in patients with multiple PPFs were similar to the overall population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-001621","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T12:26:49Z","timestamp":1628771209000},"page":"e001621","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct02886728","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02886728","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2108-0030","authenticated-orcid":false,"given":"Daniel","family":"Aletaha","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Medical University of Vienna, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-3073","authenticated-orcid":false,"given":"Ren\u00e9","family":"Westhovens","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, KU Leuven University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Gaujoux-Viala","sequence":"additional","affiliation":[{"name":"Department of Rheumatologie, Centre Hospitalier Universitaire de N\u00eemes, Nimes, France"},{"name":"UMR 1302 Institute Desbrest of Epidemiology and Public Health, INSERM, Universit\u00e9 de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-0755","authenticated-orcid":false,"given":"Giovanni","family":"Adami","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Arthritis and Rheumatism Associates PC, Wheaton, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bird","sequence":"additional","affiliation":[{"name":"St George and Sutherland Clinical School, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osvaldo Daniel","family":"Messina","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Metabolic Bone Diseases, Investigaciones Reumatol\u00f3gicas y Osteol\u00f3gicas srl, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-5642","authenticated-orcid":false,"given":"Maya H","family":"Buch","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester, Manchester, UK"},{"name":"NIHR Manchester Biomedical Research Centre, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-4662","authenticated-orcid":false,"given":"Beatrix","family":"Bartok","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyu","family":"Yin","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs","family":"Hendrikx","sequence":"additional","affiliation":[{"name":"Galapagos BV, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"2025090313260487000_7.2.e001621.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"2025090313260487000_7.2.e001621.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep155"},{"key":"2025090313260487000_7.2.e001621.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.121160"},{"key":"2025090313260487000_7.2.e001621.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.090019"},{"key":"2025090313260487000_7.2.e001621.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.21678"},{"key":"2025090313260487000_7.2.e001621.6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201348"},{"key":"2025090313260487000_7.2.e001621.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055"},{"key":"2025090313260487000_7.2.e001621.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210105"},{"key":"2025090313260487000_7.2.e001621.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210104"},{"key":"2025090313260487000_7.2.e001621.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"2025090313260487000_7.2.e001621.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219213"},{"key":"2025090313260487000_7.2.e001621.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"2025090313260487000_7.2.e001621.13","first-page":"S100","article-title":"The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313260487000_7.2.e001621.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.30129"},{"key":"2025090313260487000_7.2.e001621.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2025090313260487000_7.2.e001621.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"2025090313260487000_7.2.e001621.17","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"2025090313260487000_7.2.e001621.18","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van Der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"2025090313260487000_7.2.e001621.19","article-title":"Integrated safety analysis of filgotinib treatment for rheumatoid arthritis from 7 clinical trials","volume":"79","author":"Genovese","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-001621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:26:15Z","timestamp":1756931175000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-001621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,8,12]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1136\/rmdopen-2021-001621"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-001621","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}